$14.21
0[0.00%]
At close: Apr 24
$14.21
0[0.00%]
PreMarket: 4:00PM EDT
UroGen Pharma
(NASDAQ:URGN)Latest News for UroGen Pharma Stock (NASDAQ:URGN)
UroGen Pharma Stock (NASDAQ: URGN)
Categories: All
Thursday, April 18, 2024
Thursday, April 04, 2024
Wednesday, April 03, 2024
Monday, March 25, 2024
Monday, March 18, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
- UroGen Pharma shares are trading lower after the company reported worse-than-expected Q4 EPS results.Benzinga Newsdesk - Mar 14, 2024, 10:43AM
- UroGen Sees Full Year 2024 Net Product Revenues From Jelmyto To Be In The Range Of $95M-$102MBenzinga Newsdesk - Mar 14, 2024, 8:09AM
- UroGen Pharma Q4 EPS $(0.72) Misses $(0.68) Estimate, Sales $23.53M Beat $22.57M EstimateBenzinga Newsdesk - Mar 14, 2024, 8:06AM
- Earnings Scheduled For March 14, 2024Benzinga Insights - Mar 14, 2024, 5:52AM
Wednesday, March 13, 2024
Wednesday, January 24, 2024
Wednesday, January 17, 2024
Friday, December 29, 2023
Thursday, December 07, 2023
Wednesday, November 15, 2023
Tuesday, November 14, 2023
- Earnings Scheduled For November 14, 2023Benzinga Insights - Nov 14, 2023, 8:23AM
- UroGen Pharma Reiterates Anticipated FY23 Net Product Revenues From JELMYTO To Be In The Range Of $76M-$86MBenzinga Newsdesk - Nov 14, 2023, 8:10AM
- UroGen Pharma Q3 EPS $(0.68) Beats $(0.85) Estimate, Sales $20.85M Beat $20.03M EstimateBenzinga Newsdesk - Nov 14, 2023, 8:08AM
- Recap: UroGen Pharma Q3 EarningsBenzinga Insights - Nov 14, 2023, 8:05AM
Monday, November 13, 2023
Monday, October 09, 2023
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Friday, September 08, 2023
Thursday, August 17, 2023
Monday, August 14, 2023
Thursday, August 10, 2023
- UroGen Pharma Ltd Reiterated FY23 Revenue $76M-$86M Vs $80.74M EstBenzinga Newsdesk - Aug 10, 2023, 8:07AM
- UroGen Pharma Q2 EPS $(1.03) Beats $(1.14) Estimate, Sales $21.14M Beat $20.12M EstimateBenzinga Newsdesk - Aug 10, 2023, 8:03AM
- Earnings Scheduled For August 10, 2023Benzinga Insights - Aug 10, 2023, 6:59AM
Tuesday, August 01, 2023
Monday, July 31, 2023
Friday, July 28, 2023
- UroGen Pharma shares are trading higher on continued strength after the company yesterday announced topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution inpatients with low-grade, intermediate-risk non-muscle invasive bladder cancer.Benzinga Newsdesk - Jul 28, 2023, 3:25PM
- Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About YetChris Katje - Jul 28, 2023, 9:57AM
- Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market SessionLisa Levin - Jul 28, 2023, 6:50AM
Thursday, July 27, 2023
- UroGen Pharma shares are trading higher after the company announced topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution inpatients with low-grade, intermediate-risk non-muscle invasive bladder cancer.Benzinga Newsdesk - Jul 27, 2023, 3:26PM
- Why UroGen Pharma Stock Is Gaining Today?Vandana Singh - Jul 27, 2023, 12:46PM
- UroGen Pharma Shares Resume TradingHappy Mohamed - Jul 27, 2023, 10:31AM
- UroGen Pharma Shares Halted On Circuit Breaker To The Downside, Stock Now Up 44.8%Happy Mohamed - Jul 27, 2023, 10:26AM
- UroGen Pharma Shares Resume TradeHappy Mohamed - Jul 27, 2023, 10:25AM
- UroGen Pharma Ltd. Shares To Resume Trade At 10:25 a.m. ETHappy Mohamed - Jul 27, 2023, 10:18AM
- UroGen Announces $120M Private Placement Of 12,579,156 Shares At $9.54/ShareBenzinga Newsdesk - Jul 27, 2023, 9:57AM
- UroGen Pharma Announced Topline Data From Phase 3 Trials ATLAS And ENVISION Studying UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer; Both Trials Met Primary EndpointsBenzinga Newsdesk - Jul 27, 2023, 9:54AM